Sana Biotechnology (SANA)
(Delayed Data from NSDQ)
$5.04 USD
-0.37 (-6.84%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $5.04 0.00 (0.00%) 7:20 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Sana Biotechnology, Inc. [SANA]
Reports for Purchase
Showing records 1 - 14 ( 14 total )
Company: Sana Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
EULAR Recap: Autologous CD19 CAR-T Results Establish Early Benchmarks for Cell Therapies in Autoimmune Diseases
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Sana Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Recap: Four Clinical Programs on Track for Data in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Sana Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Recap: Clinical Data in Several Indications Expected in 2024 Could Further Validate the Platform
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Sana Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Sana Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Sana Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Hypoimmune POC Established With Positive Efficacy and Safety; Upgrading to Buy With $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Sana Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in ARDENT Study Achieved PR; Additional Data to Be Announced in 2024; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Sana Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Recap: Attention Is on ARDENT Data in 4Q23 and Early IST Data in T1D
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Sana Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Reprioritization Puts Focus on Hypoimmune-Based Therapies; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Sana Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Recap: Focus Remains on ARDENT Data in 2H23 That Could Provide Platform Validation
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Sana Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
RD Day Takeaways: Potential For Two Programs to Achieve Clinical Proof of Concept in 2023; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Sana Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Take: SC291 Phase 1 Study is Enrolling Patients With Initial Data Expected 2H23; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Sana Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
The Autologous CAR-T Therapy Pioneers Have Turned Allogeneic; Initiating at Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Sana Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
|